Drug Price Trends for IBUPROFEN-FAMOTIDIN

Average Pharmacy Cost for IBUPROFEN-FAMOTIDIN

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
IBUPROFEN-FAMOTIDIN 800-26.6 MG	72578-0214-16	0.94175	EACH	2026-05-20
IBUPROFEN-FAMOTIDIN 800-26.6 MG	67877-0626-90	0.94175	EACH	2026-05-20
IBUPROFEN-FAMOTIDIN 800-26.6 MG	31722-0315-90	0.94175	EACH	2026-05-20
IBUPROFEN-FAMOTIDIN 800-26.6 MG	49884-0366-09	0.94175	EACH	2026-05-20
IBUPROFEN-FAMOTIDIN 800-26.6 MG	67877-0626-90	0.85420	EACH	2026-04-22
IBUPROFEN-FAMOTIDIN 800-26.6 MG	31722-0315-90	0.85420	EACH	2026-04-22

Last updated: April 23, 2026

Market Analysis and Price Projections for Ibuprofen-Famotidine (Fixed-Dose Combination)

What is the product and how is it marketed?

“Ibuprofen-famotidine” is a fixed-dose combination of:

• Ibuprofen (NSAID for pain, inflammation, fever)
• Famotidine (H2-receptor antagonist for gastric acid suppression to reduce upper GI irritation risk)

In practice, commercial availability depends on country-specific approvals and branding. In many markets, the product is sold either:

• as a registered fixed-dose combination, or
• as branded single tablets under a regimen that pairs ibuprofen with famotidine.

A key market reality: ibuprofen is widely off-patent and highly commoditized; value capture for the combo typically comes from improved tolerability positioning (GI protection) and brand/channel execution, not from novel API economics.

---

What is the addressable market?

The addressable market is the overlap of:

1. OTC and prescription NSAID demand (musculoskeletal pain, dysmenorrhea, dental pain, back pain, arthritis symptom relief)
2. Populations at higher risk of NSAID-related upper GI events (older adults, history of ulcer/bleeding, concomitant risk factors)

Demand drivers

• High baseline NSAID consumption
• Ongoing physician and payer preference for “GI-protective co-therapy” strategies
• Patient preference for fewer pills via fixed-dose products

Constraint

• In many countries, the combo is evaluated against two alternatives:
  • OTC/low-cost ibuprofen alone plus H2 blockers taken separately
  • Proton pump inhibitor (PPI) strategies in prescription channels

---

How competitive is the category and what does pricing reflect?

Ibuprofen pricing anchors economics. Famotidine is also off-patent in most major markets. Pricing power comes from:

• Formulation differentiation (fixed-dose convenience)
• Brand recognition and prescriber habit (where prescription)
• Channel execution (tender pricing in institutional markets)
• Regulatory status (OTC vs prescription controls)

Competitive set (practical)

• Single-agent ibuprofen (generic, OTC-heavy)
• Co-administration: ibuprofen + famotidine
• Other GI protection: PPI co-therapy (often prescription, sometimes reimbursed)

---

What is the near-term market outlook (volume and mix)?

Near term: stable to modestly growing volumes are most likely in geographies where:

• GI safety labeling increases physician use of protective regimens
• fixed-dose combos gain formulary access
• reimbursement favors bundled GI-protection strategies

Mix shift: higher share in:

• older patients using NSAIDs chronically or intermittently
• musculoskeletal pain segments where tolerability drives repeat use
• settings with structured GI risk management

---

What are the key pricing mechanisms that set real-world prices?

Pricing typically follows three layers:

1. Wholesale acquisition cost (WAC) or list price
   • Brand level, sometimes discounted heavily.
2. Reimbursement or tender price
   • Determined by national reimbursement rules, pharmacy margins, and procurement frameworks.
3. OTC market pricing
   • Competitive with low-cost generics and parallel imports; price is often driven by shelf competitiveness.

For fixed-dose combos, payers often benchmark against:

• sum of components (ibuprofen generic + famotidine generic)
• clinical value in reducing GI adverse events (when assessed)
• administrative convenience

---

What price level should investors model? (Projection framework)

Because ibuprofen and famotidine are commoditized, the combination price usually prices as:

• a small premium vs ibuprofen alone, and
• a small discount vs “stacked” GI protection strategies when convenience matters.

Below are scenario-based price targets expressed as per-day therapy cost proxies. Actual realization depends on market, pack size, and dosage strength.

Assumed pricing structure for modeling

Let:

• Ibuprofen base cost = generic ibuprofen OTC/retail benchmark in the target market
• Famotidine add-on = generic famotidine benchmark (or included implicitly in combo pricing)
• Combo convenience premium = fixed-dose advantage, typically modest

Then:

• Combo cost/day ≈ ibuprofen base cost/day + famotidine cost/day + convenience premium

---

Price projection scenarios (per-pack and per-day proxies)

The drug product exists in different dosing strengths depending on local registrations. To keep projections decision-useful without pretending a single universal dose, model per-day cost using dose-agnostic pricing ratios: combo typically trades at a mid-single to low-double digit premium versus ibuprofen alone when sold as fixed-dose.

Scenario table (modeled ranges)

Assume an average adult daily NSAID dose bracket (commonly 1200–2400 mg/day for ibuprofen in many indications depending on labeling), with the fixed-dose combo aligning to common regimens.

Market segment	Competitive anchor	Combo convenience premium vs ibuprofen alone	Modeled retail per-day (local currency)	Modeled payer per-day (reimbursed/tender)
OTC retail (no tender)	Generic ibuprofen	+5% to +20%	Low to mid premium to ibuprofen alone	Not applicable
Prescription reimbursed	Generic ibuprofen + famotidine co-pay	+0% to +10%	Near component-sum	Typically lowest within class
Institutional tender	Bulk generic components	-5% to +5% vs component-sum	Often at or below component-sum	Lowest price bands

Interpretation for business planning

• No exclusivity economics: pricing is constrained by component generics.
• Sustainable price requires either (i) protected fixed-dose registration in that jurisdiction, or (ii) formulary preference based on GI-risk management.

---

What do price projections imply for revenue growth?

Revenue is a product of:

• Unit volume (packs)
• Net price (after discounts, rebates, and tenders)

In commoditized fixed-dose combos, long-run growth usually comes from:

• share gains in GI-risk cohorts
• expansion into additional geographies/formulary lists
• pack-size optimization (adherence-driven)
• payer contracting based on pharmacoeconomic arguments (GI safety)

Net price likely:

• declines gradually as additional generics enter or as procurement pressure increases
• stabilizes where tender frameworks lock pricing or where fixed-dose convenience is embedded in standard regimens

---

How long does pricing support last?

Without API patent leverage (ibuprofen and famotidine are off-patent), durability depends on:

• combination registration status
• local exclusivity for formulation or indication
• manufacturing and supply constraints
• regulatory changes that shift guidance toward or away from H2-based protection

Typical pattern in similar fixed-dose, component-generic combos

• Initial commercialization or re-launch: higher list price with discounts
• Medium term: list price compression tied to competition
• Longer term: pricing floors set by procurement and margin regulations

---

Key Takeaways

• Ibuprofen-famotidine is priced in a commoditized framework dominated by the generic economics of ibuprofen and famotidine.
• Net pricing is usually constrained to a modest premium vs ibuprofen alone and benchmarks tightly against the sum of components.
• Revenue growth is more likely to come from share and volume in GI-risk cohorts and formulary inclusion than from sustained price escalation.
• Projection should use a scenario model: OTC retail pricing shows modest premiums; prescription and tender pricing tends toward component-sum levels.

FAQs

1. Is ibuprofen-famotidine expected to command high pricing power?
   No. Pricing is typically constrained by generic ibuprofen and famotidine benchmarks.

2. What drives adoption of the fixed-dose combo versus taking the drugs separately?
   Convenience, adherence, and prescriber protocolization in GI-risk populations.

3. How should investors model net price versus list price?
   Prefer net price assumptions aligned to typical discounted and tender outcomes; list price alone usually overstates realized economics.

4. Do PPIs compete directly with this combo?
   Yes in many prescription settings, with PPI strategies often preferred in higher-risk GI profiles.

5. What is the most sensitive variable in revenue forecasting?
   Formulary/tender access and resultant net price more than unit list price.

---

References

[1] PubChem. “Ibuprofen.” https://pubchem.ncbi.nlm.nih.gov/compound/ibuprofen
[2] PubChem. “Famotidine.” https://pubchem.ncbi.nlm.nih.gov/compound/famotidine
[3] EMA. “Ibuprofen: EPAR product information.” https://www.ema.europa.eu/
[4] FDA. “Ibuprofen (OTC and prescription labeling references).” https://www.accessdata.fda.gov/
[5] FDA. “Famotidine (OTC and prescription labeling references).” https://www.accessdata.fda.gov/